Collegium Pharmaceutical Inc. (COLL)
NASDAQ:COLL
Want to see COLL full AI Analyst Report?
COLL Stock Chart & Stats
$34.41
$3.70(12.70%)
At close: 4:00 PM EST
$34.41
$3.70(12.70%)
Day’s Range― - ―
52-Week Range$26.72 - $50.79
Previous CloseN/A
Volume233.62K
Average Volume (3M)588.09K
Market Cap
$1.11B
Enterprise Value$1.78B
Total Cash (Recent Filing)$406.53M
Total Debt (Recent Filing)$940.56M
Price to Earnings (P/E)21.6
Beta0.39
Next Earnings
May 07, 2026EPS Estimate
1.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.04
Shares Outstanding32,406,967
10 Day Avg. Volume588,702
30 Day Avg. Volume588,086
Financial Highlights & Ratios
PEG Ratio-3.12
Price to Book (P/B)4.87
Price to Sales (P/S)1.88
P/FCF Ratio4.48
Enterprise Value/Market Cap1.60
Enterprise Value/Revenue2.28
Enterprise Value/Gross Profit3.85
Enterprise Value/Ebitda2.97
Forecast
1Y Price Target
$54.17Price Target Upside57.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)7.31
Revenue Forecast (FY)$811.03M
Bulls Say, Bears Say
Bulls Say
Acquisition Expands Product LineupAcquisition of AZSTARYS expands the ADHD franchise by adding a differentiated, established product with existing prescriptions, increasing long-term revenue visibility.
Balance Sheet StrengthStrong balance sheet flexibility and low leverage enhance capacity to pursue accretive strategic actions that can support growth and shareholder returns.
Commercial Synergies And ProfitabilityProjected commercial synergies and the ability to leverage an existing ADHD commercial infrastructure should improve margins and overall profitability.
Bears Say
Authorized Generic CompetitionAuthorized generic launches for flagship pain products increase competitive pressure on the pain franchise, raising the risk of sales erosion and margin compression.
Deal Valuation RiskDeal valuation appears elevated and may pressure returns if the new asset does not fully offset revenue declines from other products facing competition.
Limited Analyst InsightProvided analyst excerpt contains limited operational and financial takeaways, which reduces transparency and makes it harder for investors to assess the recommendation.
Collegium Pharmaceutical News
COLL FAQ
What was Collegium Pharmaceutical Inc.’s price range in the past 12 months?
Collegium Pharmaceutical Inc. lowest stock price was $26.72 and its highest was $50.79 in the past 12 months.
What is Collegium Pharmaceutical Inc.’s market cap?
Collegium Pharmaceutical Inc.’s market cap is $1.11B.
When is Collegium Pharmaceutical Inc.’s upcoming earnings report date?
Collegium Pharmaceutical Inc.’s upcoming earnings report date is May 07, 2026 which is in 4 days.
How were Collegium Pharmaceutical Inc.’s earnings last quarter?
Collegium Pharmaceutical Inc. released its earnings results on Feb 26, 2026. The company reported $2.04 earnings per share for the quarter, missing the consensus estimate of $2.139 by -$0.099.
Is Collegium Pharmaceutical Inc. overvalued?
According to Wall Street analysts Collegium Pharmaceutical Inc.’s price is currently Undervalued.
Does Collegium Pharmaceutical Inc. pay dividends?
Collegium Pharmaceutical Inc. does not currently pay dividends.
What is Collegium Pharmaceutical Inc.’s EPS estimate?
Collegium Pharmaceutical Inc.’s EPS estimate is 1.52.
How many shares outstanding does Collegium Pharmaceutical Inc. have?
Collegium Pharmaceutical Inc. has 32,406,967 shares outstanding.
What happened to Collegium Pharmaceutical Inc.’s price movement after its last earnings report?
Collegium Pharmaceutical Inc. reported an EPS of $2.04 in its last earnings report, missing expectations of $2.139. Following the earnings report the stock price went down -3.344%.
Which hedge fund is a major shareholder of Collegium Pharmaceutical Inc.?
Currently, no hedge funds are holding shares in COLL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Collegium Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.17 (57.42% Upside)
$54.17 (57.42% Upside)
Blogger Sentiment
Bullish
COLL Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 48.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 2.1%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
27.39%
12-Months-Change
Fundamentals
Return on Equity
24.11%
Trailing 12-Months
Asset Growth
1.35%
Trailing 12-Months
Company Description
Collegium Pharmaceutical Inc.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
COLL Company Deck
COLL Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasizes strong, broad-based commercial performance (notably Jornay PM) and robust financial outcomes for 2025 — record revenue, record adjusted EBITDA, strong cash generation, and materially improved leverage. Management reiterated disciplined capital deployment, added liquidity via a $980M syndicated facility, and expects Jornay to be a key growth driver in 2026 (guiding Jarday revenue +~31% YoY). However, near-term headwinds and risks include substantial increases in operating expenses due to commercialization investments, elevated gross-to-net rates (≈64%), expected seasonal Q1 pressure, a Q4 decline in Xtampza, and the impact of an authorized generic for Nucynta (partially mitigated by profit share). Overall, the positives (revenue growth, cash flow, leverage improvement, Jornay momentum, strategic financing) materially outweigh the lowlights, which are largely investment- and seasonality-driven.View all COLL earnings summariesCOLL Stock 12 Month Forecast
Average Price Target
$54.17
▲(57.42% Upside)
Technical Analysis
―
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Ownership Overview
12.74% Insiders
32.77% Mutual Funds
2.71% Other Institutional Investors
23.41% Public Companies and
Individual Investors